Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.48 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.47 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.44 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.43 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 1.00 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | DAO | P14920 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28968677 | 1.00 | AOC3 (1.00) | AOC3LOXL2CA2NPC1RAB9A | |
| SCHEMBL37667 | 0.98 | AOC3 (1.00) | AOC3LOXL2CA2NPC1RAB9A | |
| SCHEMBL29363162 | 0.98 | AOC3 (1.00) | AOC3LOXL2CA2NPC1RAB9A | |
| Iodide SCHEMBL2316310 | 0.95 | AOC3 (0.95) | AOC3LOXL2CA2NPC1RAB9A | |
| Pyrrole SCHEMBL27718192 | 0.87 | AOC3 (0.80) | AOC3LOXL2CA2NPC1RAB9A | |
| Urea SCHEMBL28162531 | 0.87 | AOC3 (0.80) | AOC3LOXL2CA2NPC1RAB9A | |
| Pyrrole SCHEMBL412879 | 0.87 | AOC3 (0.80) | AOC3LOXL2CA2NPC1RAB9A | |
| SCHEMBL28494735 | 0.87 | AOC3 (0.80) | AOC3LOXL2CA2NPC1RAB9A | |
| SCHEMBL28124326 | 0.86 | AOC3 (0.77) | AOC3LOXL2CA2NPC1RAB9A | |
| SCHEMBL27747908 | 0.82 | AOC3 (0.71) | AOC3LOXL2CA2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112018270-B | Preparation method of quantum dot film and preparation method of quantum dot light-emitting diode | TCL科技集团股份有限公司 | 2021-09-10 | — | — | CN | claimed |
| CN-112018270-A | Preparation method of quantum dot film and preparation method of quantum dot light-emitting diode | TCL集团股份有限公司 | 2020-12-01 | — | — | CN | claimed |
| CN-115052860-B | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-115052860-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-113736447-A | Composition, preparation method of composition, quantum dot light-emitting device and display panel | TCL华星光电技术有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-112018270-B | Preparation method of quantum dot film and preparation method of quantum dot light-emitting diode | TCL科技集团股份有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-112018270-A | Preparation method of quantum dot film and preparation method of quantum dot light-emitting diode | TCL集团股份有限公司 | 2020-12-01 | — | — | CN | disclosed |
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| CN-1312246-A | Process for preparing carboxylic acid | BAYER AG (DE) | 2001-09-12 | — | — | CN | disclosed |
| CN-1067393-C | Novel pyrimido [1, 2-a ] indoles | BAYER AG (DE) | 2001-06-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | CA2 99/4885FLT3 166/4885GAA 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.